摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

钙二(4-羟基丁酸酯) | 82316-97-0

中文名称
钙二(4-羟基丁酸酯)
中文别名
——
英文名称
Calcium bis(4-hydroxybutyrate)
英文别名
calcium;4-hydroxybutanoate
钙二(4-羟基丁酸酯)化学式
CAS
82316-97-0
化学式
C8H14CaO6
mdl
——
分子量
246.27
InChiKey
AZRRVLSHRWGNRS-UHFFFAOYSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.36
  • 重原子数:
    15
  • 可旋转键数:
    8
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    121
  • 氢给体数:
    2
  • 氢受体数:
    6

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
乳酸钠羟酸是γ-羟基丁酸(GHB)的盐。GHB是一种内源性物质,通常在母乳中可以发现少量。大剂量的GHB曾被用作滥用物质。有母亲在治疗发作性睡病时服用乳酸钠,并成功哺乳婴儿。在典型的每晚两次剂量的治疗方案下,通常应该从第一次服药时开始到第二次服药后4到6小时不哺乳,白天可以继续哺乳。目前没有关于在哺乳期间滥用GHB作为药物的使用或安全性的信息。监测婴儿是否出现镇静、进食不良和体重增长不良的情况。 ◉ 对哺乳婴儿的影响:一位妇女在怀孕和哺乳期间每天两次服用4.5克乳酸钠治疗发作性睡病和猝倒症。她哺乳了她的婴儿(哺乳的程度和时间未说明)。未报告婴儿出现不良反应。 一位患有发作性睡病的妇女在怀孕和产后期间每晚10点和凌晨2点各服用4克乳酸钠,以及每天服用20毫克氟西汀和5毫克西替利嗪。她在服用乳酸钠后4小时内不哺乳,除了在每次服用乳酸钠前泵取母乳或哺乳婴儿。婴儿在6个月大时开始引入固体食物,之前是纯母乳喂养或用母乳喂养。婴儿在2、4和6个月时进行了评估,使用的是年龄和阶段问卷,结果在正常范围内,婴儿的生长和儿科医生对婴儿的生长和发展的临床印象也是正常的。 ◉ 对泌乳和母乳的影响:截至修订日期,未找到相关的已发布信息。
◉ Summary of Use during Lactation:Sodium, calcium, magnesium and potassium oxybate are salts of gamma-hydroxybutyric acid (GHB). GHB is an endogenous substance and low amounts are normally found in breastmilk. Large doses of GHB have been used as a substance of abuse. Infants have been successfully breastfed by mothers taking sodium oxybate therapeutically for narcolepsy. With the typical 2 doses per night treatment regimen, nursing should usually be withheld from the time of the first dose to 4 to 6 hours after the second dose and breastfeeding can be continued during the day. No information is available on the use or safety of GHB as a drug of abuse during breastfeeding. Monitor the infant for sedation, poor feeding and poor weight gain. ◉ Effects in Breastfed Infants:A woman was taking 4.5 grams of sodium oxybate twice daily (exact times not reported) for narcolepsy and cataplexy throughout pregnancy and lactation. She breastfed her infant (extent and times not stated). No adverse infant effects were reported. A woman with narcolepsy took sodium oxybate 4 grams each night at 10 pm and 2 am as well as fluoxetine 20 mg and cetirizine 5 mg daily throughout pregnancy and postpartum. She breastfed her infant except for 4 hours after the 10 pm oxybate dose and 4 hours after the 2 am dose. She either pumped breastmilk or breastfed her infant just before each dose of oxybate. The infant was exclusively breastfed or breastmilk fed for 6 months when solids were introduced. The infant was evaluated at 2, 4 and 6 months with the Ages and Stages Questionnaires, which were withing the normal range as were the infant's growth and pediatrician's clinical impressions regarding the infant's growth and development. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.
来源:Drugs and Lactation Database (LactMed)

反应信息

点击查看最新优质反应信息

文献信息

  • Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
    申请人:Orphan Medical Inc.
    公开号:EP1316309A1
    公开(公告)日:2003-06-04
    Disclosed are formulations of gamma-hydroxybutyrate in an acqueous medium that are resistant to microbial growth . Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with thesc stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal;, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    所公开的是γ-羟基丁酸盐在介质中的制剂,这种制剂能够抵抗微生物的生长。还公开了γ-羟基丁酸的制剂,这些制剂还能防止转化为GBL。本发明公开了使用 GHB 的稳定制剂治疗睡眠障碍(包括嗜睡症)的方法。本发明还提供了治疗酒精和鸦片制剂戒断、生长激素平降低、颅内压增高和病人身体疼痛的方法。
  • Butyrate and beta-hydroxybutyrate compositions
    申请人:Cavaleri Franco
    公开号:US10376482B2
    公开(公告)日:2019-08-13
    Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.
    本发明公开了向人提供外源性和治疗有效酮体的组合物和方法。这些组合物主要由(a)纯化的丁酸盐(或其酯类丙酸盐)和(b)纯化的β-羟基丁酸盐(或其酯类丙酸盐)组成。组合物还可进一步包括其他药理活性剂,如乙酰-左旋肉碱、R-α-硫辛酸、绿茶提取物维生素以及这些药剂的各种组合。这些方法包括通过口服给药组合物为人提供外源性酮供应,该组合物每天可有效提供 2000-5000 毫克短链脂肪酸(如丁酸)和 5000-10000 毫克酮(如 beta-羟基丁酸)。
  • Methods for delivering compounds into a cell
    申请人:ImaRX Pharmaceutical Corporation
    公开号:US20010031740A1
    公开(公告)日:2001-10-18
    The present invention is directed, inter alia, to a method for delivering a compound into a cell comprising administering to the cell the compound to be delivered, an organic halide, and/or a carrier. Ultrasound may also be applied, if desired.
    本发明主要涉及一种向细胞内输送化合物的方法,该方法包括向细胞内输送待输送的化合物、有机卤化物和/或载体。如果需要,还可以使用超声波。
  • EP0935415A4
    申请人:——
    公开号:EP0935415A4
    公开(公告)日:2002-08-14
  • METHODS FOR DELIVERING COMPOUNDS INTO A CELL
    申请人:IMARX PHARMACEUTICAL CORP.
    公开号:EP0935415A1
    公开(公告)日:1999-08-18
查看更多